AICAR: AMPK Activator Dosing, Research & WADA Status (2026)

Table of Contents
- What AICAR is and how it works
- Clinical trial doses
- “Bodybuilder” and biohacker dosing – and why it’s questionable
- Side effects and safety
- Drug interactions
- Cycle Lengths
- Lab Monitoring
- Storage & Travel
- WADA / sport-testing status
- Reconstitution
- How AICAR compares to other AMPK activators
- FAQ
TL;DR: AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) is technically not a peptide – it’s a nucleoside analog – but it sits next to peptides in research-supplier catalogs and biohacker stacks because it activates AMP-activated protein kinase (AMPK) and was the original “exercise-in-a-needle” molecule. AICAR has been in human clinical trials since 1991, with the largest being the MACE trial in cardiac surgery patients (~2,700 subjects, IV infusion 100 mcg/kg/min during surgery). It is prohibited at all times by WADA under hormone and metabolic modulators (S4.4, AMPK activators) and is not FDA-approved for any indication. This guide covers what the evidence supports and what biohackers buying research-grade product should know about safety, sport-testing risk, and the gap between published clinical doses and bro-science protocols.
For other longevity-adjacent peptides, see our epitalon guide, MOTS-c guide, and SS-31 / FORZINITY guide.
What AICAR is and how it works
AICAR is converted intracellularly to ZMP (AICA ribotide), an AMP analog that binds the gamma subunit of AMPK and activates it. AMPK is the cell’s master energy-sensor: when ATP runs low (exercise, fasting, hypoxia) AMPK phosphorylates downstream targets that switch metabolism toward catabolism – increasing fatty-acid oxidation, glucose uptake (insulin-independent), and mitochondrial biogenesis, while suppressing lipogenesis and protein synthesis through mTORC1.
The 2008 Salk Institute mouse study from the Evans lab is the source of AICAR’s “exercise mimetic” reputation: sedentary mice given AICAR for four weeks ran ~44% farther on a treadmill than untreated controls. The catch – which is rarely communicated cleanly – is that the mouse dose was 500 mg/kg/day for four weeks. The human-equivalent dose is enormous and was never replicated as an exercise-replacement protocol in humans.
Clinical trial doses
The infusion doses studied in cardiac surgery were narrow and brief – designed to cardioprotect during ischemia/reperfusion, not to “boost endurance”:
| Trial / context | Dose | Route | Duration |
|---|---|---|---|
| Phase 1 PK (1991) | 5 mg/kg | IV bolus | Single |
| Cardiac surgery (MACE, Phase 3) | 100 mcg/kg/min | IV infusion | ~6 hours peri-op |
| Lymphoma (preclinical/early phase) | 0.05–0.5 mg/kg/day | IV / SC | Up to 28 days |
The MACE program did not show a significant cardioprotective benefit and AICAR development for that indication was halted. There has never been a chronic-administration human trial at the doses biohackers use.
“Bodybuilder” and biohacker dosing – and why it’s questionable
Reported research-grade protocols circulating online land in two ranges:
- IV / SC daily: 50–100 mg per dose, daily, for 4–8 weeks
- Sublingual / oral: 200–500 mg per dose (oral bioavailability is poor; most ingested AICAR is excreted unchanged)
There is no peer-reviewed human study supporting either of those protocols for fat loss, endurance, or longevity. The signaling rationale (AMPK → fatty-acid oxidation, GLUT4 translocation) is real, but the leap from “AMPK activation in mouse muscle for 4 weeks at 500 mg/kg” to “100 mg SC daily in a 90 kg human” is not supported by pharmacokinetic or efficacy data.
Side effects and safety
Across published clinical trials, AICAR has been generally well tolerated at therapeutic infusion doses. The signals to watch are documented in the PMC systematic review:
- Transient hyperuricemia – AICAR is a purine derivative; uric acid rises with administration.
- Mild lactic acidosis at high doses.
- Hypoglycemia, particularly in fasted states (insulin-independent glucose uptake).
- AMPK-independent effects – the systematic review specifically calls out that many published “AMPK effects” of AICAR may actually be off-target ZMP effects on other purine pathways.
No hepatotoxicity, nephrotoxicity, or bone-marrow suppression has been reported in human trials at the doses studied.
Drug interactions
Drug interactions to know
Educational summary only, not medical advice. Consult your prescriber. See full interactions lookup.
Cycle Lengths
Cycling summary: WADA S4.4 banned in and out of competition since 2009. No established human protocol.
Cycle timing should be informed by the peptide’s half-life, receptor tachyphylaxis profile (if applicable), and personal response monitored through lab work. Log both on-cycle and off-cycle biomarkers to understand recovery kinetics.
Lab Monitoring
AICAR is a longevity or antioxidant class peptide. Because longevity effects are inherently long-arc, lab monitoring focuses on aging biomarkers, mitochondrial/oxidative status where applicable, and general health surveillance.
Baseline (before starting): comprehensive metabolic panel (CMP) with LFTs and renal function, CBC, hs-CRP, lipid panel with ApoB if available, HbA1c, fasting insulin, IGF-1 (age-adjusted), TSH, sex hormones age-appropriate, homocysteine, vitamin D. Optional research-grade: telomere length via DTC labs (Life Length, Repeat Diagnostics), epigenetic age via TruDiagnostic, GlycanAge.
During use: repeat inflammatory + metabolic labs every 3-6 months (hs-CRP, HbA1c, ApoB). Repeat CMP + CBC every 6 months. Repeat telomere or epigenetic markers annually only — these are expensive, high-variance, and mostly informational rather than clinical decision-making tools.
What to flag to a physician: significant CBC or CMP shifts across two draws, persistent fatigue, unexplained weight or appetite change, any new symptom that could reflect systemic inflammation or metabolic dysregulation.
For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.
Storage & Travel
Storage
Lyophilized powder: Freezer -20°C (-4°F) long-term; refrigerated short term acceptable.
Reconstituted: Reconstituted stability limited; use within days. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.
Travel
Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.
International travel: AICAR is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.
Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.
Emergency out-of-fridge: reconstituted AICAR at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.
WADA / sport-testing status
AICAR was added to the WADA Prohibited List in 2011 and is prohibited in-competition and out-of-competition under category S4.4 (AMPK activators). Detection methods are well-developed because endogenous AICAR is normally low; exogenous administration produces a measurable AICAR/creatinine spike in urine. Per USADA’s plain-language explainer, athletes risk sanction even from compounded or contaminated supplements.
Reconstitution
AICAR is not a peptide and dissolves in sterile water or saline at typical research concentrations. A 50 mg vial reconstituted with 1 mL bacteriostatic water yields 50 mg/mL. Use the Peptide Toolkit calculator for syringe-unit math.
How AICAR compares to other AMPK activators
Metformin is the most-studied AMPK activator with decades of human safety data – though it activates AMPK indirectly via mitochondrial complex I inhibition rather than direct binding. MOTS-c is a mitochondrial-derived peptide that acts upstream and has actual peptide character. SS-31 / elamipretide targets cardiolipin and improves mitochondrial bioenergetics through an entirely different mechanism (and is now FDA-approved for Barth syndrome).
FAQ
Is AICAR FDA-approved? No. It has been in clinical trials but no indication has reached approval.
Is AICAR an “exercise mimetic” in humans? Not at any dose tested in humans. The mouse data does not extrapolate.
Will AICAR show on a drug test? Yes. WADA-accredited labs detect it in urine for weeks. Banned in-competition and out-of-competition.
Is AICAR a peptide? No – it’s a nucleoside analog. It’s grouped with peptides because of its research-chemical sales channel and biohacker use.
References
- Narkar VA, Downes M, Yu RT, et al. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405-15.
- Visnjic D, Lalic H, Dembitz V, et al. AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review. Cells. 2021;10(5):1095.
- WADA. The Prohibited List 2026.
- USADA. What Athletes Should Know About AICAR and Other Prohibited AMPK Activators.






